Guggenheim Capital LLC Dexcom Inc Transaction History

Guggenheim Capital LLC

$12 Billion
Q4 2024

A detailed history of Guggenheim Capital LLC transactions in Dexcom Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 115,717 shares of DXCM stock, worth $8.54 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

115,717

Previous 145,953 20.72%

Holding current value

$8.54 Million

Previous $9.78 Million 8.0%

% of portfolio

0.07%

Previous 0.07%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$65.68 - $81.01 $1.99 Million - $2.45 Million	-30,236 Reduced 20.72%	115,717 $9 Million
Q3 2024 Nov 13, 2024	BUY	$64.0 - $116.06 $449,152 - $814,509	7,018 Added 5.05%	145,953 $9.78 Million
Q2 2024 Aug 14, 2024	BUY	$110.31 - $140.45 $881,156 - $1.12 Million	7,988 Added 6.1%	138,935 $15.8 Million
Q1 2024 May 14, 2024	SELL	$114.22 - $140.1 $693,086 - $850,126	-6,068 Reduced 4.43%	130,947 $18.2 Million
Q4 2023 Feb 14, 2024	BUY	$75.49 - $124.16 $1.28 Million - $2.11 Million	16,995 Added 14.16%	137,015 $17 Million
Q3 2023 Nov 14, 2023	BUY	$86.06 - $137.93 $701,216 - $1.12 Million	8,148 Added 7.28%	120,020 $11.2 Million
Q2 2023 Aug 11, 2023	SELL	$112.47 - $130.98 $517,924 - $603,162	-4,605 Reduced 3.95%	111,872 $14.4 Million
Q1 2023 May 10, 2023	BUY	$104.0 - $122.92 $1.15 Million - $1.36 Million	11,037 Added 10.47%	116,477 $13.5 Million
Q4 2022 Feb 14, 2023	SELL	$84.98 - $122.67 $2.43 Million - $3.5 Million	-28,563 Reduced 21.32%	105,440 $11.9 Million
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $4.35 Million - $5.37 Million	-57,013 Reduced 29.85%	134,003 $10.8 Million
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $9.59 Million - $18.8 Million	141,121 Added 282.84%	191,016 $14.2 Million
Q1 2022 May 16, 2022	SELL	$94.08 - $130.2 $1.74 Million - $2.41 Million	-18,511 Reduced 27.06%	49,895 $25.5 Million
Q4 2021 Feb 14, 2022	BUY	$129.87 - $162.82 $1.17 Million - $1.47 Million	9,004 Added 15.16%	68,406 $36.7 Million
Q3 2021 Nov 15, 2021	SELL	$106.71 - $143.18 $609,954 - $818,416	-5,716 Reduced 8.78%	59,402 $32.5 Million
Q2 2021 Aug 13, 2021	BUY	$80.99 - $107.93 $809,576 - $1.08 Million	9,996 Added 18.13%	65,118 $27.8 Million
Q1 2021 May 13, 2021	SELL	$84.79 - $104.74 $1.04 Million - $1.29 Million	-12,282 Reduced 18.22%	55,122 $19.8 Million
Q4 2020 Feb 16, 2021	BUY	$78.0 - $104.5 $767,052 - $1.03 Million	9,834 Added 17.08%	67,404 $24.9 Million
Q3 2020 Nov 13, 2020	SELL	$95.51 - $112.95 $1,910 - $2,259	-20 Reduced 0.03%	57,570 $23.7 Million
Q2 2020 Aug 14, 2020	BUY	$62.68 - $105.34 $1.77 Million - $2.98 Million	28,243 Added 96.24%	57,590 $23.3 Million
Q1 2020 Jun 02, 2020	SELL	$47.79 - $75.63 $740,888 - $1.17 Million	-15,503 Reduced 34.57%	29,347 $7.9 Million
Q4 2019 Feb 14, 2020	BUY	$36.62 - $57.29 $211,260 - $330,506	5,769 Added 14.76%	44,850 $9.81 Million
Q3 2019 Nov 14, 2019	SELL	$35.53 - $43.8 $614,988 - $758,134	-17,309 Reduced 30.7%	39,081 $5.83 Million
Q2 2019 Aug 14, 2019	SELL	$27.84 - $38.92 $42,790 - $59,820	-1,537 Reduced 2.65%	56,390 $8.45 Million
Q1 2019 May 15, 2019	SELL	$28.07 - $38.18 $2,975 - $4,047	-106 Reduced 0.18%	57,927 $6.9 Million
Q4 2018 Feb 14, 2019	BUY	$26.99 - $37.37 $29,662 - $41,069	1,099 Added 1.93%	58,033 $6.95 Million
Q3 2018 Nov 14, 2018	BUY	$23.35 - $36.72 $75,770 - $119,156	3,245 Added 6.04%	56,934 $8.14 Million
Q2 2018 Aug 14, 2018	BUY	$17.54 - $25.22 $48,901 - $70,313	2,788 Added 5.48%	53,689 $5.1 Million
Q1 2018 May 15, 2018	BUY	$13.06 - $18.54 $141,439 - $200,788	10,830 Added 27.03%	50,901 $3.78 Million
Q4 2017 Feb 14, 2018	BUY	$11.12 - $15.38 $34,316 - $47,462	3,086 Added 8.34%	40,071 $2.3 Million
Q3 2017 Nov 14, 2017	BUY	$11.36 - $18.98 $420,149 - $701,975	36,985	36,985 $1.81 Million

Others Institutions Holding DXCM

# of Institutions

1,084

Shares Held

352M

Call Options Held

8.45M

Put Options Held

5.75M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $28.5B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Dexcom Inc Transaction History